NASDAQ · Biotechnology

Definium Therapeutics, Inc. (DFTX) Stock

$37.39 +9.39% NASDAQ: DFTX Healthcare

Valuation

MetricValue
Price$37.39
Market Cap$4.96B
P/E Ratio-10.87
P/B Ratio4.51
P/S Ratio0.00
EPS (TTM)$-2.06
52-Week High$49.20
52-Week Low$12.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-85.23%
ROA-31.79%
ROCE-23.81%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio6.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-94.0M$-66.0M$-94.0M$-104.0M$-166.0M
Net Profit$-93.0M$-57.0M$-96.0M$-109.0M$-184.0M
EPS$-3.40$-1.53$-2.44$-0.15$-2.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$164.0M$170.0M$125.0M$302.0M$440.0M
Total Liabilities$12.0M$19.0M$46.0M$61.0M$108.0M
Cash$134.0M$142.0M$100.0M$274.0M$258.0M
Borrowings$0$0$14.0M$22.0M$0

Latest News

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva IPO-Edge.com · Jul 22, 2026 Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? Simply Wall St. · Jul 22, 2026 How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story Simply Wall St. · Jul 22, 2026 Psychedelic drugs are going mainstream Financial Times · Jul 21, 2026 Definium Therapeutics Announces New Employee Inducement Grants Business Wire · Jul 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-50.0M$-64.0M$-79.0M$-132.0M
Investing Cash Flow$0$0$0$0$-152.0M
Financing Cash Flow$17.0M$17.0M$0$-8.0M$-13.0M
Net Cash Flow$53.0M$9.0M$-42.0M$174.0M$-16.0M
Free Cash Flow$-46.0M$-50.0M$-64.0M$-79.0M$-132.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.15
EV / EBITDA-12.79
FCF Yield-3.36%
Quick Ratio6.95
Interest Coverage-16.92
Return 1Y326.07%
Return 3Y846.47%
Return 5Y-9.01%

Ownership

Insiders Held1.33%
Institutions Held73.86%
Institutions Float Held74.86%
Institutional HolderSharesReport Date
Blackrock Inc.8,480,2302026-03-31
Driehaus Capital Management, LLC5,911,8892026-03-31
Avoro Capital Advisors LLC5,000,0002026-03-31
Janus Henderson Group PLC3,556,0412026-03-31
Deep Track Capital, Lp3,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANROAlto Neuroscience, Inc. $24.95 +3.81% -9.71 $875.42M 0.00%
ATHEAlterity Therapeutics Limited $4.70 -5.62% -6.89 $42.60M 0.00%
AXSMAxsome Therapeutics, Inc. $169.38 -0.41% -49.17 $8.72B 0.00%
GHRSGH Research PLC $21.21 +3.72% -22.71 $1.45B 0.00%
LBRXLB Pharmaceuticals Inc $37.71 +8.96% -12.45 $1.08B 0.00%

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. (DFTX) stock trades at $37.39 with a market capitalization of $4.96B. The stock is valued at a price-to-earnings (P/E) ratio of -10.87, price-to-book of 4.51, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.88 and $49.20, and currently trades 24.0% below its 52-week high.

On profitability, Definium Therapeutics, Inc. generates a return on equity (ROE) of -85.23%, return on capital employed of -23.81%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.15 +0.30% JNJ Johnson & Johnson $260.24 +1.47% ABBV AbbVie Inc. $276.46 +1.48% MRK Merck & Company, Inc. Common Stock (new) $146.28 +2.74% UNH UnitedHealth Group Incorporated Common Stock (DE) $381.63 +2.88% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.30 +0.82% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.73 +2.47% ABT Abbott Laboratories $99.51 +1.04% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides